Interim Results

AI SummaryClose X

Thalia Therapeutics plc announced its unaudited interim results for the six months ended 30 June 2026, reporting an operating loss of £757,192, an increase from £470,216 in the prior year period, with cash reserves standing at £1,502,217. The company has undergone a strategic transformation, appointing a new CEO and changing its name, and has advanced its development pipeline by acquiring Sanmirna Therapeutics Inc., adding the clinical-stage miRisten for Acute Myeloid Leukaemia and initiating preclinical work on a dual-acting siRNA for cardiovascular disease. The company also raised £2.75 million through an oversubscribed placing, which, along with existing cash, is expected to fund operations through mid-2027, including the completion of the miRisten Phase 1 trial targeted for H1 2027.

Disclaimer*

UK 100

Latest directors dealings